Insider · CIK 0001733143
Ralf Kuriyel
Files at RGEN (REPLIGEN CORP). First filing Mar 12, 2024, latest Mar 12, 2024.
In brief
Ralf Kuriyel files SEC Form 4 as officer at RGEN (REPLIGEN CORP). Since Mar 12, 2024, Ralf Kuriyel has reported 0 open-market buys worth $0 and 1 open-market sell worth $681k, the latest filed on Mar 12, 2024.
A track record needs three past buys with six months of prices behind them; Ralf Kuriyel has 0, so none is measured yet.
The newest scored trade: sold $681k of RGEN on Mar 11, 2024, filed Mar 12, 2024, scored 41 (moderate).
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
RGEN: REPLIGEN CORP
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | REPLIGEN CORP | $681k 3,517 shares | -13% | +69% from low-7% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Mar 11, 2024 | RGEN Repligen Corporation | 3,517 0.01% of outstanding | $681k | Mar 11, 2024 | none |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 5, 2026 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +5,284 | $0.00 | $0 | 20,062 | Mar 23, 2026 |
| Mar 5, 2026 | RGEN REPLIGEN CORP | AGrant or award Stock Option (Right to Buy)derivative | +5,669 | $0.00 | $0 | 5,669 | Mar 23, 2026 |
| Mar 4, 2026 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +125 | $0.00 | $0 | 14,820 | Mar 5, 2026 |
| Mar 4, 2026 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -42 | $125.84 | $5,285 | 14,778 | Mar 5, 2026 |
| Feb 27, 2026 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -444 | $128.73 | $57k | 15,618 | Mar 3, 2026 |
| Mar 2, 2026 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -923 | $124.97 | $115k | 14,695 | Mar 3, 2026 |
| Mar 3, 2025 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +4,826 | $0.00 | $0 | 16,448 | Mar 4, 2025 |
| Mar 3, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -386 | $155.38 | $60k | 16,062 | Mar 4, 2025 |
| Mar 3, 2025 | RGEN REPLIGEN CORP | AGrant or award Stock Option (Right to Buy)derivative | +4,542 | $0.00 | $0 | 4,542 | Mar 4, 2025 |
| Feb 27, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -391 | $156.54 | $61k | 11,622 | Feb 28, 2025 |
| Feb 24, 2025 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -275 | $164.74 | $45k | 12,013 | Feb 25, 2025 |
| Mar 11, 2024 | RGEN REPLIGEN CORP | MOption exercise Common Stock | +1,271 | $86.10 | $109k | 27,777 | Mar 12, 2024 |
| Mar 11, 2024 | RGEN REPLIGEN CORP | SOpen-market sale Common Stock | -3,517 | $193.73 | $681k | 24,260 | Mar 12, 2024 |
| Mar 11, 2024 | RGEN REPLIGEN CORP | MOption exercise Stock Option (Right to Buy)derivative | +1,271 | $0.00 | $0 | 0 | Mar 12, 2024 |
| Mar 7, 2024 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -386 | $195.72 | $76k | 26,506 | Mar 7, 2024 |
| Mar 4, 2024 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -135 | $193.99 | $26k | 26,892 | Mar 6, 2024 |
| Feb 29, 2024 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +404 | $0.00 | $0 | 27,480 | Mar 4, 2024 |
| Mar 1, 2024 | RGEN REPLIGEN CORP | FTax withholding Common Stock | -453 | $191.79 | $87k | 27,027 | Mar 4, 2024 |
| Feb 27, 2024 | RGEN REPLIGEN CORP | AGrant or award Common Stock | +3,520 | $0.00 | $0 | 27,076 | Feb 29, 2024 |
| Feb 27, 2024 | RGEN REPLIGEN CORP | AGrant or award Stock Option (Right to Buy)derivative | +3,497 | $0.00 | $0 | 3,497 | Feb 29, 2024 |
Questions about Ralf Kuriyel
Answered from the filings on this page, as of the latest one.
Is Ralf Kuriyel buying or selling?
Not in the last 12 months. Ralf Kuriyel's latest open-market trade on SEC Form 4 was sold $681k of RGEN on Mar 11, 2024.
How did Ralf Kuriyel's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Ralf Kuriyel has 0.
Where does Ralf Kuriyel file Form 4?
Ralf Kuriyel has filed Form 4 at RGEN (REPLIGEN CORP) as Senior VP, R&D. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.